Watch out, Pfizer and Alnylam. AstraZeneca wades deeper into rare diseases with Ionis tie-up
Just months after wrapping up the Alexion acquisition, AstraZeneca is beefing up its newly established rare disease portfolio with a collaboration with Ionis Pharmace...
Continue Reading →
